Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.09.287771v1?rss=1 Authors: Mohammed, A. A., Elkhalifa, M. E., Elamin, K. E., Mohammed, R. A., Ibrahim, M. E., Dirar, A. I., Migdar, S. H., Hamid, M. A., Elawad, E. H., Abdelsalam, S. O., Hassan, M. A. Abstract: Background: Lujo virus LUJV is a highly fatal human pathogen belonging to the Arenaviridae family. Lujo virus causes viral hemorrhagic fever VHF. An In silico molecular docking was performed on the GPC domain of Lujo virus in complex with the first CUB domain of neuropilin-2. The aim of this study is to predict effective epitope-based vaccine against glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches. Methods and Materials: glycoprotein GPC precursor of Lujo virus Sequence was retrieved from NCBI. Different prediction tools were used to analyze the nominees epitopes in BepiPred-2.0: Sequential B-Cell Epitope Predictor for B-cell, T-cell MHC class II & I. Then the proposed peptides were docked using Autodock 4.0 software program. Results and Conclusions: The proposed and promising peptides FWYLNHTKL and YMFSVTLCI show a very strong binding affinity to MHC class I & II alleles with high population coverage for the world, South Africa and Sudan. This indicates a strong potential to formulate a new vaccine especially with the peptide YMFSVTLCI which is likely to be the first proposed epitope-based vaccine against glycoprotein GPC of the Lujo virus. This study recommends an in-vivo assessment for the most promising peptides especially FWYLNHTKL, YMFSVTLCI and LPCPKPHRLR. Copy rights belong to original authors. Visit the link for more info